{"success":true,"data":{"pressRelease":{"id":"102172","rtpr_id":"nGNX6Pns3S","ticker":"ALVO","exchange":"NASDAQ","all_tickers":["ALVO"],"title":"Alvotech announces successful closure of FDA inspection of manufacturing facility","author":"Globe Newswire","published_at":"2026-07-29T13:25:35.658Z","article_body":"REYKJAVIK, Iceland, July 29, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO;\nALVO-SDB) (the “Company”), a global biotechnology company specializing in\nthe development and manufacture of biosimilar medicines for patients\nworldwide, today announced that the U.S. Food and Drug Administration (FDA)\nhas closed its inspection of the company’s manufacturing facility in\nReykjavik, Iceland, conducted in May 2026. The FDA has confirmed the\ninspection classification of the manufacturing site is Voluntary Action\nIndicated (VAI).\n\n“This is an important milestone for Alvotech and reflects the significant\nwork our teams have undertaken to further strengthen our quality systems and\nmanufacturing operations,” said Lisa Graver, CEO of Alvotech. “With the\nconclusion of the FDA’s recent inspection, we are confident that the actions\nwe have taken have effectively addressed the observations identified. We\ncontinue to work with the FDA to advance our recent Biologics Licence\nApplications towards approval.”\n\nAlvotech continues to advance its pipeline of biosimilar candidates. The\ncompany recently announced the resubmission of Biologics License Applications\n(BLAs) for AVT05, Alvotech’s biosimilar to Simponi® (golimumab), and AVT06,\nAlvotech’s biosimilar to Eylea® (aflibercept), and the acceptance by the\nFDA of the submission of a BLA for AVT16, Alvotech’s proposed biosimilar to\nEntyvio® (vedolizumab) to the FDA in June 2026.\n\nAlvotech continues to work closely with health authorities worldwide to bring\nhigh-quality, affordable biologic medicines to patients.\n\nFor further information, contact:\n\nMedia\nBenedikt Stefansson\nSarah MacLeod\nalvotech.media@alvotech.com\n\nInvestors\nDr. Balaji V Prasad (US)\nBenedikt Stefansson (IS)\nalvotech.ir@alvotech.com\n\nAbout Alvotech\nAlvotech is a biotechnology company, founded by Robert Wessman, focused solely\non the development and manufacture of biosimilar medicines for patients\nworldwide. Alvotech seeks to be a global leader in the biosimilar space by\ndelivering high-quality, cost-effective products and services, enabled by a\nfully integrated approach and broad in-house capabilities. Five biosimilars\nare already approved and marketed in multiple global markets, including\nbiosimilars to Humira® (adalimumab), Stelara® (ustekinumab), Simponi®\n(golimumab), Eylea® (aflibercept) and Prolia®/Xgeva® (denosumab). The\ncurrent development pipeline includes 13 disclosed biosimilar candidates aimed\nat treating autoimmune disorders, eye disorders, osteoporosis, respiratory\ndisease, and cancer. Alvotech has formed a network of strategic commercial\npartnerships to provide global reach and leverage local expertise in markets\nthat include the United States, Europe, Japan, China and other Asian\ncountries, and large parts of South America, Africa and the Middle East. For\nmore information, please visit https://www.alvotech.com.\n\nFor more information, please visit our investor portal\n(https://www.globenewswire.com/Tracker?data=n4nWujGIaZuvPVsNI7cNyBmogwj1aWx_VzlJu8_im-5T9w9L7uxmH7YntZtgA4x8wRkYfXTym0TmnD_J6WO7N4R8YpxBK_vFJBCvjvgRlhc=),\nand our website\n(https://www.globenewswire.com/Tracker?data=5oi4OtGhGTh1CwT2OjMqFKPTleir5cUPQkfC_bjhZlsLVql2zmthA_M8soKuEjCs6eLPKXqqYIWngRl_EMnJ-A==)\nor follow us on social media on LinkedIn\n(https://www.globenewswire.com/Tracker?data=ZiW-epdSHa41cjqSDoR0qmdTjzZP77GHje5drXVONPtmPF58x2s9M9DLgpraJO5t7CT_H-0hj7YdrcN3kJ51qxbfASn8elEPN3cPiS8R1Zw=),\nFacebook\n(https://www.globenewswire.com/Tracker?data=mt6pi0mP2ZJ72MRM-zYdXy6hM-SdAuoKAddr_Wm1MOKIH74ImweB0MjnterQJHBCV-j4F6DR58CYtDjvoaYie1ON1DnkeWVSFiC4sVoh_Oc=),\nInstagram\n(https://www.globenewswire.com/Tracker?data=wxkaaHY17aEE8FGFrbwAmNxCjDb3B6nPju2pFfhfNbvsdUjBNXYnPC40ETrI-nNcJcWMtVEweMiP1NYYRjLXueZWeqajNVgx1ShwSkAO2uI=)\nand YouTube\n(https://www.globenewswire.com/Tracker?data=Cc2mWa3E2jDh72uKRT2D3mRFaKOSxxRsC2u3RgJFGRm-ne0ouTPCs8v12TEN25cVQE7-wsN7oQNpDj-94WtCvzSyJARIhYFUkvdUi1y9BjY=).\n\nNone of the information on the Alvotech website shall be deemed part of this\npress release.\n\nUse of trademarks\n\nSimponi® and Simponi Aria® are trademarks of Johnson & Johnson. Eylea® is a\ntrademark of Regeneron Pharmaceuticals Inc. Entyvio® is a registered\ntrademark of Millennium Pharmaceuticals, Inc.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/17a8091d-68a6-47c1-968e-fcced99f1d44)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX6Pns3S","title":"Alvotech announces successful closure of FDA inspection of manufacturing facility","author":"Globe Newswire","ticker":"ALVO","created":"2026-07-29T13:25:35.658Z","tickers":["ALVO"],"exchange":"NASDAQ","article_body":"REYKJAVIK, Iceland, July 29, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO;\nALVO-SDB) (the “Company”), a global biotechnology company specializing in\nthe development and manufacture of biosimilar medicines for patients\nworldwide, today announced that the U.S. Food and Drug Administration (FDA)\nhas closed its inspection of the company’s manufacturing facility in\nReykjavik, Iceland, conducted in May 2026. The FDA has confirmed the\ninspection classification of the manufacturing site is Voluntary Action\nIndicated (VAI).\n\n“This is an important milestone for Alvotech and reflects the significant\nwork our teams have undertaken to further strengthen our quality systems and\nmanufacturing operations,” said Lisa Graver, CEO of Alvotech. “With the\nconclusion of the FDA’s recent inspection, we are confident that the actions\nwe have taken have effectively addressed the observations identified. We\ncontinue to work with the FDA to advance our recent Biologics Licence\nApplications towards approval.”\n\nAlvotech continues to advance its pipeline of biosimilar candidates. The\ncompany recently announced the resubmission of Biologics License Applications\n(BLAs) for AVT05, Alvotech’s biosimilar to Simponi® (golimumab), and AVT06,\nAlvotech’s biosimilar to Eylea® (aflibercept), and the acceptance by the\nFDA of the submission of a BLA for AVT16, Alvotech’s proposed biosimilar to\nEntyvio® (vedolizumab) to the FDA in June 2026.\n\nAlvotech continues to work closely with health authorities worldwide to bring\nhigh-quality, affordable biologic medicines to patients.\n\nFor further information, contact:\n\nMedia\nBenedikt Stefansson\nSarah MacLeod\nalvotech.media@alvotech.com\n\nInvestors\nDr. Balaji V Prasad (US)\nBenedikt Stefansson (IS)\nalvotech.ir@alvotech.com\n\nAbout Alvotech\nAlvotech is a biotechnology company, founded by Robert Wessman, focused solely\non the development and manufacture of biosimilar medicines for patients\nworldwide. Alvotech seeks to be a global leader in the biosimilar space by\ndelivering high-quality, cost-effective products and services, enabled by a\nfully integrated approach and broad in-house capabilities. Five biosimilars\nare already approved and marketed in multiple global markets, including\nbiosimilars to Humira® (adalimumab), Stelara® (ustekinumab), Simponi®\n(golimumab), Eylea® (aflibercept) and Prolia®/Xgeva® (denosumab). The\ncurrent development pipeline includes 13 disclosed biosimilar candidates aimed\nat treating autoimmune disorders, eye disorders, osteoporosis, respiratory\ndisease, and cancer. Alvotech has formed a network of strategic commercial\npartnerships to provide global reach and leverage local expertise in markets\nthat include the United States, Europe, Japan, China and other Asian\ncountries, and large parts of South America, Africa and the Middle East. For\nmore information, please visit https://www.alvotech.com.\n\nFor more information, please visit our investor portal\n(https://www.globenewswire.com/Tracker?data=n4nWujGIaZuvPVsNI7cNyBmogwj1aWx_VzlJu8_im-5T9w9L7uxmH7YntZtgA4x8wRkYfXTym0TmnD_J6WO7N4R8YpxBK_vFJBCvjvgRlhc=),\nand our website\n(https://www.globenewswire.com/Tracker?data=5oi4OtGhGTh1CwT2OjMqFKPTleir5cUPQkfC_bjhZlsLVql2zmthA_M8soKuEjCs6eLPKXqqYIWngRl_EMnJ-A==)\nor follow us on social media on LinkedIn\n(https://www.globenewswire.com/Tracker?data=ZiW-epdSHa41cjqSDoR0qmdTjzZP77GHje5drXVONPtmPF58x2s9M9DLgpraJO5t7CT_H-0hj7YdrcN3kJ51qxbfASn8elEPN3cPiS8R1Zw=),\nFacebook\n(https://www.globenewswire.com/Tracker?data=mt6pi0mP2ZJ72MRM-zYdXy6hM-SdAuoKAddr_Wm1MOKIH74ImweB0MjnterQJHBCV-j4F6DR58CYtDjvoaYie1ON1DnkeWVSFiC4sVoh_Oc=),\nInstagram\n(https://www.globenewswire.com/Tracker?data=wxkaaHY17aEE8FGFrbwAmNxCjDb3B6nPju2pFfhfNbvsdUjBNXYnPC40ETrI-nNcJcWMtVEweMiP1NYYRjLXueZWeqajNVgx1ShwSkAO2uI=)\nand YouTube\n(https://www.globenewswire.com/Tracker?data=Cc2mWa3E2jDh72uKRT2D3mRFaKOSxxRsC2u3RgJFGRm-ne0ouTPCs8v12TEN25cVQE7-wsN7oQNpDj-94WtCvzSyJARIhYFUkvdUi1y9BjY=).\n\nNone of the information on the Alvotech website shall be deemed part of this\npress release.\n\nUse of trademarks\n\nSimponi® and Simponi Aria® are trademarks of Johnson & Johnson. Eylea® is a\ntrademark of Regeneron Pharmaceuticals Inc. Entyvio® is a registered\ntrademark of Millennium Pharmaceuticals, Inc.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/17a8091d-68a6-47c1-968e-fcced99f1d44)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-07-29T13:25:35.736697451Z","server_sent_at_ms":1785331535736},"received_at":"2026-07-29T13:25:35.788Z","source_url":"https://www.globenewswire.com/news-release/2026/07/29/3335322/0/en/alvotech-announces-successful-closure-of-fda-inspection-of-manufacturing-facility.html"},"analysis":{"id":"91199","press_release_id":"102172","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["VAI classification indicates objectionable conditions were found, though no immediate regulatory action is recommended"],"eventType":"regulatory","narrative":"The FDA closed its inspection of Alvotech’s Reykjavik manufacturing facility, conducted in May 2026, assigning the site a Voluntary Action Indicated (VAI) classification.\n\nCEO Lisa Graver stated that the milestone reflects strengthened quality systems and that the company has effectively addressed prior observations, allowing it to advance Biologics License Applications.\n\nAlvotech is actively resubmitting BLAs for AVT05 (Simponi biosimilar) and AVT06 (Eylea biosimilar), while its BLA for AVT16 (Entyvio biosimilar) was accepted by the FDA in June 2026.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Manufacturing hurdle cleared with VAI status, path to US approvals unblocked."},"keyFigures":{"customDimensions":{"approved_marketed":5,"pipeline_candidates":13}},"quotedText":"This is an important milestone for Alvotech and reflects the significant work our teams have undertaken to further strengthen our quality systems and manufacturing operations","namedEntities":{"people":[{"name":"Lisa Graver","role":"CEO"},{"name":"Robert Wessman","role":"Founder"},{"name":"Benedikt Stefansson","role":"Media/Investor Contact"},{"name":"Sarah MacLeod","role":"Media Contact"},{"name":"Dr. Balaji V Prasad","role":"Investor Contact"}],"products":["AVT05","Simponi","AVT06","Eylea","AVT16","Entyvio","Humira","Stelara","Prolia","Xgeva"],"companies":[{"name":"Johnson & Johnson","relationship":"trademark owner"},{"name":"Regeneron Pharmaceuticals Inc.","relationship":"trademark owner"},{"name":"Millennium Pharmaceuticals, Inc.","relationship":"trademark owner"}],"dollarAmounts":[]},"materialImpact":{"score":4,"reasoning":"The closure of the FDA inspection with a VAI classification removes a major overhang regarding the company's manufacturing quality systems, which is a critical prerequisite for U.S. product approvals and commercialization."},"tickerRelevance":{"others":[],"primary":"ALVO"},"globalImportance":25,"audienceRelevance":30,"eventTypeSecondary":["operations_update"],"importanceComponents":{"tickerTier":"small-mid-cap","eventGravity":"regulatory/operational","sectorWeight":"biotech"}},"event_type":"regulatory","event_type_secondary":["operations_update"],"sentiment":"bullish","material_impact_score":4,"narrative":"The FDA closed its inspection of Alvotech’s Reykjavik manufacturing facility, conducted in May 2026, assigning the site a Voluntary Action Indicated (VAI) classification.\n\nCEO Lisa Graver stated that the milestone reflects strengthened quality systems and that the company has effectively addressed prior observations, allowing it to advance Biologics License Applications.\n\nAlvotech is actively resubmitting BLAs for AVT05 (Simponi biosimilar) and AVT06 (Eylea biosimilar), while its BLA for AVT16 (Entyvio biosimilar) was accepted by the FDA in June 2026.","key_figures":{"customDimensions":{"approved_marketed":5,"pipeline_candidates":13}},"named_entities":{"people":[{"name":"Lisa Graver","role":"CEO"},{"name":"Robert Wessman","role":"Founder"},{"name":"Benedikt Stefansson","role":"Media/Investor Contact"},{"name":"Sarah MacLeod","role":"Media Contact"},{"name":"Dr. Balaji V Prasad","role":"Investor Contact"}],"products":["AVT05","Simponi","AVT06","Eylea","AVT16","Entyvio","Humira","Stelara","Prolia","Xgeva"],"companies":[{"name":"Johnson & Johnson","relationship":"trademark owner"},{"name":"Regeneron Pharmaceuticals Inc.","relationship":"trademark owner"},{"name":"Millennium Pharmaceuticals, Inc.","relationship":"trademark owner"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-07-29T18:52:29.443Z","global_importance":25,"audience_relevance":30,"importance_components":{"tickerTier":"small-mid-cap","eventGravity":"regulatory/operational","sectorWeight":"biotech"}},"durationMs":null,"modelName":"glm-4.7"}}